{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:55:04Z","timestamp":1786118104990,"version":"build-2736575974"},"reference-count":26,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Atopic dermatitis is commonly associated with depressive symptoms and fatigue, which significantly impact quality of life. While clinical trials suggest beneficial effects of dupilumab on mental health, real-world evidence remains limited. This longitudinal cohort study analysed data from adult patients treated with dupilumab in the TREATgermany registry. Subgroups were defined by baseline Center for Epidemiologic Studies Depression Scale (CES D) scores \u226516 (clinically significant depressive symptoms) and Fatigue Severity Scale (FSS) scores &gt;4 (significant fatigue). Clinical severity (Eczema Area and Severity Index [EASI], objective Scoring Atopic Dermatitis [oSCORAD]), quality of life (DLQI), psychological symptoms, treatment needs and benefits (PNQ, PBI) and drug survival were assessed over 12 months. Among 633 patients, those with elevated baseline CES-D (n=309) or FSS (n=281) scores reported greater disease burden measured by DLQI, while EASI and oSCORAD did not differ between subgroups. Both CES-D and FSS scores decreased markedly within the first 3 months. Sleep and social functioning needs were more frequently reported in high-burden subgroups and more often fulfilled after 12 months. Drug survival was comparable across subgroups. Dupilumab treatment was associated with significant improvements in depressive symptoms, fatigue and skin severity. Patients with higher baseline mental health burden showed comparable improvements in patient relevant domains, supporting the broad relevance of dupilumab in real-world atopic dermatitis care.<\/jats:p>","DOI":"10.2340\/actadv.v106.adv-2026-0616","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:08:37Z","timestamp":1786028917000},"source":"Crossref","is-referenced-by-count":0,"title":["Improvement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry"],"prefix":"10.2340","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4806-599X","authenticated-orcid":false,"given":"Stephan","family":"Traidl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Cornelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Siegels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Zacharias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annice","family":"Heratizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Honstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"St\u00f6lzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Ramaker-Brunke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schulz-Kiesow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Quist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilo","family":"Biedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Asefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Sch\u00e4kel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Meinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Handrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Werfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"165051","doi-asserted-by":"crossref","unstructured":"Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy 2018; 73: 1284\u20131293.","DOI":"10.1111\/all.13401"},{"key":"165052","doi-asserted-by":"crossref","unstructured":"Traidl S, Werfel T, Traidl-Hoffmann C. Atopic eczema: pathophysiological findings as the beginning of a new era of therapeutic options. Handb Exp Pharmacol 2022; 268: 101\u2013115.","DOI":"10.1007\/164_2021_492"},{"key":"165053","doi-asserted-by":"crossref","unstructured":"Thyssen JP, Hamann CR, Linneberg A, Dantoft TM, Skov L, Gislason GH, et al. Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. Allergy 2018; 73: 214\u2013220.","DOI":"10.1111\/all.13231"},{"key":"165054","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. Br J Dermatol 2019; 181: 554\u2013565.","DOI":"10.1111\/bjd.17683"},{"key":"165055","doi-asserted-by":"crossref","unstructured":"Sockler PG, Hooper SR, Abuabara K, Ma EZ, Radtke S, Bao A, et al. Atopic dermatitis, cognitive function and psychiatric comorbidities across early childhood and adolescence in a population-based UK birth cohort. Br J Dermatol 2024; 190: 501\u2013509.","DOI":"10.1093\/bjd\/ljad486"},{"key":"165056","doi-asserted-by":"crossref","unstructured":"Schonmann Y, Mansfield KE, Hayes JF, Abuabara K, Roberts A, Smeeth L, et al. Atopic eczema in adulthood and risk of depression and anxiety: a population-based cohort study. J Allergy Clin Immunol Pract 2020; 8: 248\u2013257.","DOI":"10.1016\/j.jaip.2019.08.030"},{"key":"165057","doi-asserted-by":"crossref","unstructured":"Bawany F, Northcott CA, Beck LA, Pigeon WR. Sleep disturbances and atopic dermatitis: relationships, methods for assessment, and therapies. J Allergy Clin Immunol Pract 2021; 9: 1488\u20131500.","DOI":"10.1016\/j.jaip.2020.12.007"},{"key":"165058","doi-asserted-by":"crossref","unstructured":"Ferrucci SM, Tavecchio S, Angileri L, Surace T, Berti E, Buoli M. Factors associated with affective symptoms and quality of life in patients with atopic dermatitis. Acta Derm Venereol 2021; 101: adv00590.","DOI":"10.2340\/00015555-3922"},{"key":"165059","doi-asserted-by":"crossref","unstructured":"Fan R, Leasure AC, Damsky W, Cohen JM. Alcohol use disorder among adults with atopic dermatitis: a case-control study in the All of Us research program. J Am Acad Dermatol 2022; 87: 1378\u20131380.","DOI":"10.1016\/j.jaad.2022.09.015"},{"key":"165060","doi-asserted-by":"crossref","unstructured":"Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol 2013; 131: 428\u2013433.","DOI":"10.1016\/j.jaci.2012.10.041"},{"key":"165061","doi-asserted-by":"crossref","unstructured":"L\u00f6nndahl L, Abdelhadi S, Holst M, Lonne-Rahm SB, Nordlind K, Johansson B. Psychological stress and atopic dermatitis: a focus group study. Ann Dermatol 2023; 35: 342\u2013347.","DOI":"10.5021\/ad.22.035"},{"key":"165062","doi-asserted-by":"crossref","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335\u20132348.","DOI":"10.1056\/NEJMoa1610020"},{"key":"165063","doi-asserted-by":"crossref","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371: 130\u2013139.","DOI":"10.1056\/NEJMoa1314768"},{"key":"165064","doi-asserted-by":"crossref","unstructured":"St\u00f6lzl D, Sander N, Heratizadeh A, Haufe E, Harder I, Abraham S, et al. Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry. Br J Dermatol 2022; 187: 1022\u20131024.","DOI":"10.1111\/bjd.21794"},{"key":"165065","doi-asserted-by":"crossref","unstructured":"Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol 2016; 75: 506\u2013515.","DOI":"10.1016\/j.jaad.2016.04.054"},{"key":"165066","doi-asserted-by":"crossref","unstructured":"Cork MJ, Eckert L, Simpson EL, Armstrong A, Barbarot S, Puig L, et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat 2020; 31: 606\u2013614.","DOI":"10.1080\/09546634.2019.1612836"},{"key":"165067","doi-asserted-by":"crossref","unstructured":"Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. Dupilumab impact on psychiatric and sleep disorder risk reduction in atopic dermatitis: a population-based cohort study. Ann Allergy Asthma Immunol 2025; 134: 333\u2013340.","DOI":"10.1016\/j.anai.2024.11.016"},{"key":"165068","doi-asserted-by":"crossref","unstructured":"Honstein T, Kind B, St\u00f6lzl D, Harder I, M\u00fcller S, Birkner T, et al. The importance of registries in clinical practice: insights from the national atopic dermatitis registry TREATgermany. Allergol Select 2025; 9: 40\u201346.","DOI":"10.5414\/ALX02545E"},{"key":"165069","doi-asserted-by":"crossref","unstructured":"Heratizadeh A, Haufe E, St\u00f6lzl D, Abraham S, Heinrich L, Kleinheinz A, et al. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. J Eur Acad Dermatol Venereol 2020; 34: 1263\u20131272.","DOI":"10.1111\/jdv.16078"},{"key":"165070","doi-asserted-by":"crossref","unstructured":"Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR. Validation of the fatigue severity scale in a Swiss cohort. Sleep 2008; 31: 1601\u20131607.","DOI":"10.1093\/sleep\/31.11.1601"},{"key":"165071","doi-asserted-by":"crossref","unstructured":"Carleton RN, Thibodeau MA, Teale MJN, Welch PG, Abrams MP, Robinson T, et al. The center for epidemiologic studies depression scale: a review with a theoretical and empirical examination of item content and factor structure. PLoS One 2013; 8: e58067.","DOI":"10.1371\/journal.pone.0058067"},{"key":"165072","doi-asserted-by":"crossref","unstructured":"Roberts RE, Vernon SW. The center for epidemiologic studies depression scale: its use in a community sample. Am J Psychiatry 1983; 140: 41\u201346.","DOI":"10.1176\/ajp.140.1.41"},{"key":"165073","unstructured":"R: the R project for statistical computing. [cited 2025 November 8]."},{"key":"165074","doi-asserted-by":"crossref","unstructured":"Rooney S, McFadyen DA, Wood DL, Moffat DF, Paul PL. Minimally important difference of the fatigue severity scale and modified fatigue impact scale in people with multiple sclerosis. Mult Scler Relat Disord 2019; 35: 158\u2013163.","DOI":"10.1016\/j.msard.2019.07.028"},{"key":"165075","doi-asserted-by":"crossref","unstructured":"Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582\u2013592.","DOI":"10.1097\/01.MLR.0000062554.74615.4C"},{"key":"165076","doi-asserted-by":"crossref","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287\u20132303.","DOI":"10.1016\/S0140-6736(17)31191-1"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46656\/55052","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46656\/55053","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46656\/55054","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46656\/55052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:08:42Z","timestamp":1786028922000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/46656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":26,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.adv-2026-0616","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}